Patents by Inventor Stephen Goutman

Stephen Goutman has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 11452724
    Abstract: Provided herein are methods for treating, delaying progression of, or reducing the severity of amyotrophic lateral sclerosis (ALS) in a subject through administration of therapeutically effective amounts of agents (e.g., JAK kinase inhibitors (e.g., tofacitinib)) capable of interfering with central nervous system related natural killer cell (NK) levels and function.
    Type: Grant
    Filed: April 22, 2020
    Date of Patent: September 27, 2022
    Assignee: The Regents of the University of Michigan
    Inventors: Eva L. Feldman, Ben Murdock, Stephen Goutman, Stacey Jacoby
  • Publication number: 20200253977
    Abstract: Provided herein are methods for treating, delaying progression of, or reducing the severity of amyotrophic lateral sclerosis (ALS) in a subject through administration of therapeutically effective amounts of agents (e.g., JAK kinase inhibitors (e.g., tofacitinib)) capable of interfering with central nervous system related natural killer cell (NK) levels and function.
    Type: Application
    Filed: April 22, 2020
    Publication date: August 13, 2020
    Inventors: Eva L. Feldman, Ben Murdock, Stephen Goutman, Stacey Jacoby
  • Patent number: 10660895
    Abstract: Provided herein are methods for treating, delaying progression of, or reducing the severity of amyotrophic lateral sclerosis (ALS) in a subject through administration of therapeutically effective amounts of agents (e.g., JAK kinase inhibitors (e.g., tofacitinib)) capable of interfering with central nervous system related natural killer cell (NK) levels and function.
    Type: Grant
    Filed: August 13, 2019
    Date of Patent: May 26, 2020
    Assignee: The Regents of the University of Michigan
    Inventors: Eva L. Feldman, Ben Murdock, Stephen Goutman, Stacey Jacoby
  • Publication number: 20200046705
    Abstract: Provided herein are methods for treating, delaying progression of, or reducing the severity of amyotrophic lateral sclerosis (ALS) in a subject through administration of therapeutically effective amounts of agents (e.g., JAK kinase inhibitors (e.g., tofacitinib)) capable of interfering with central nervous system related natural killer cell (NK) levels and function.
    Type: Application
    Filed: August 13, 2019
    Publication date: February 13, 2020
    Inventors: Eva L. Feldman, Ben Murdock, Stephen Goutman, Stacey Jacoby